Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...
BioPharma Dive

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

Vertex to buy Crinetics for $10 billion in rare-diseases push

By Puyaan Singh July 6 (Reuters) - Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of ...

Vertex spending $10B to buy San Diego biotech in largest-ever acquisition

Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk ...
Reuters

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis ...